

---

## Redeye Initiates Coverage of Senzime

Redeye initiates coverage of Senzime, a Swedish medtech company specialising in quantitative neuromuscular patient monitoring with its flagship device, the TetraGraph system. With a rapidly expanding installed base and rising utilisation rates, we see a compelling growth trajectory ahead. Our fair value range indicates solid upside potential, with quarterly reports demonstrating solid growth as the primary trigger for the share price.

**Read more and download the Research Report.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Redeye Initiates Coverage of Senzime**